7 completed, 7 terminated, 1 active not recruiting, 1 enrolling by invitation. 7 Phase 1, 6 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Terminated 4, Active not recruiting 1, Completed 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 3, Terminated 2, Active not recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Hodgkins Lymphoma: new trials by email Literature Review of Hodgkins Lymphoma trials Research Report on Hodgkins Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). TAA-specific CTLs - Hodgkins Lymphoma, Non Hodgkins Lymphoma | Phase 1 | Withdrawn | Baylor College of Medicine | 2024-04-01 | 2024-10-22 | |
| Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) Avelumab - Hodgkins Lymphoma | Phase 1 | Terminated | Pfizer | 34 | 2016-03-10 | 2020-04-24 |
| 3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma EBV CTL's, Peripheral Blood Donor - Non-Hodgkins Lymphoma, Hodgkins Lymphoma | Phase 1 | Completed | New York Medical College | 1 | 2014-01-01 | 2017-12-22 |
| Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment Administration of hyperbaric oxygen - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Not applicable | Completed | University of Kansas Medical Center | 15 | 2013-06-01 | 2017-06-12 |
| Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma allogeneic donor derived LMP specific cytotoxic T-lymphocyte - Hodgkins Lymphoma | Phase 2 | Terminated | New York Medical College | 2 | 2013-01-01 | 2017-12-22 |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning Fludarabine monophosphate, Busulfan, Stem Cell Infusion - Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 201 | 2012-04-11 | 2023-06-29 |
| Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation Allogeneic stem cell transplant - Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia | Terminated | National Cancer Institute (NCI) | 56 | 2011-03-30 | 2018-06-06 | |
| TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation TXA127 300 mcg/kg/day, TXA127 1000 mcg/kg/day - Double Cord Blood Transplant, Acute Myelogenous Leukemia | Phase 1 | Terminated | Tarix Pharmaceuticals | 20 | 2011-01-01 | 2020-12-08 |
| Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders EPOCH-F/R, FLAG, Transplant Preparative Regimen (Flu/Cy/Mes) - Leukemia, Non-Hodgkins Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 4 | 2009-08-25 | 2019-12-17 |
| Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies Oncaspar, Doxil, Decadron - Non-hodgkins Lymphoma, Hodgkins Lymphoma | Phase 2 | Terminated | Milton S. Hershey Medical Center | 13 | 2009-03-01 | 2017-07-24 |
| Brown Fat Activity and White Fat Accumulation Hodgkins Lymphoma, Non-hodgkins Lymphoma | Completed | Children's Hospital Los Angeles | 32 | 2008-10-01 | 2012-01-25 | |
| Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft - Leukemia, Myelodysplastic Syndrome | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 86 | 2008-08-12 | 2022-12-08 |
| HD18 for Advanced Stages in Hodgkins Lymphoma Rituximab, BEACOPP escalated - Hodgkins Lymphoma | Phase 3 | Completed | University of Cologne | 1500 | 2008-05-01 | 2020-11-13 |
| Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES, LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES - Hodgkins Lymphoma, Non-Hodgkin Lymphoma | Phase 1 | Terminated | Baylor College of Medicine | 6 | 2006-09-01 | 2012-05-24 |
| Biology Studies of Hematologic Cancers Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome (MDS) | Enrolling by invitation | National Cancer Institute (NCI) | 550 | 2004-02-24 | 2026-10-21 | |
| Protection of Ovarian Function in Female Patients With Hodgkin Lymphoma 8 cycles BEACOPPesc plus oral contraceptive, 8 cycles BEACOPPesc plus Goserelin - Hodgkins Lymphoma | Phase 2 | Completed | University of Cologne | 60 | 2004-01-01 | 2012-06-25 |
Hodgkin Disease (17) · Lymphoma, Non-Hodgkin (12) · Leukemia (6) · Leukemia, Myeloid, Acute (6) · Lymphoma (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Myelodysplastic Syndromes (5) · Multiple Myeloma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Recurrence (2) · Anemia, Refractory, with Excess of Blasts (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia, B-Cell (1)
Hemic and Lymphatic Diseases (17) · Immune System Diseases (17) · Immunoproliferative Disorders (17) · Lymphatic Diseases (17) · Neoplasms (17) · Neoplasms by Histologic Type (17) · Lymphoproliferative Disorders (16) · Lymphoma (11) · Hematologic Diseases (8) · Bone Marrow Diseases (7) · Leukemia, Myeloid (7) · Disease Attributes (6) · Leukemia, Lymphoid (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6)
Cyclophosphamide (2) · Filgrastim (2) · Tacrolimus (2) · fludarabine phosphate (2) · Bone Marrow Transplantation (1) · Busulfan (1) · Calcium Dobesilate (1) · Contraceptives, Oral (1) · Goserelin (1) · Granulocyte Colony-Stimulating Factor (1) · Melphalan (1) · Mesna (1) · Methotrexate (1) · Mycophenolic Acid (1) · Radiotherapy (1)
National Cancer Institute (NCI) (3) · Baylor College of Medicine (2) · New York Medical College (2) · University of Cologne (2) · Children's Hospital Los Angeles (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Milton S. Hershey Medical Center (1) · Ossium Health, Inc. (1) · Pfizer (1) · Tarix Pharmaceuticals (1) · University of Kansas Medical Center (1)
United States (15) · Germany (1) · Italy (1) · United Kingdom (1)
Andreas Engert, Prof. (1) · Catherine Bollard, MD (1) · John W Glod, M.D. (1) · Joseph J. Drabick, MD (1) · Juliet Barker, MBBS (1) · Lauren Scherer, MD (1) · Mitchell Cairo, MD (1) · Mitchell S Cairo, MD (1) · Omar Aljitawi, MD (1) · Ronald E Gress, M.D. (1) · Steven Z Pavletic, M.D. (1) · Uday Popat, MD (1) · Uday R Popat, MD (1)
PMID 20305034, PMID 21168855, PMID 21245691, PMID 21404026, PMID 22048045, PMID 22456659, PMID 23225085, PMID 23416850, PMID 27760758, PMID 28236583, PMID 29061295, PMID 30010775, PMID 30166329, PMID 30389035, PMID 34048679, PMID 34477818, PMID 40135712, PMID 41074963, PMID 42379221
2015 (1)